Guide contents
Open in calculatorCompound briefing
SS-31 (also known as Elamipretide, MTP-131 or Bendavia) is a synthetic aromatic-cationic tetrapeptide (D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane at levels up to 1,000-fold higher than in the cytosol. It binds cardiolipin — a phospholipid unique to mitochondria — stabilising cristae architecture, protecting electron-transport-chain integrity and restoring ATP production in dysfunctional mitochondria. It has progressed through Phase 3 clinical trials for Barth syndrome, primary mitochondrial myopathy, dry AMD and heart failure with preserved ejection fraction (HFpEF).
The research question
SS-31 concentrates at cardiolipin-rich mitochondrial membranes rather than acting as a general antioxidant. Cristae structure, respiratory-chain organisation and ATP output are therefore more relevant measurements than a generic oxidative-stress score.
Mechanism & research themes
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilising cristae structure and optimising the supercomplex assembly of Complexes I–IV. This restores efficient electron flow, reduces mitochondrial reactive oxygen species (ROS) generation at source, preserves the inner-membrane potential and rescues ATP synthesis. Uniquely, uptake does not require an active membrane potential — allowing it to enter and rescue already-injured mitochondria.
Cardiolipin stabilisation and cristae-architecture preservation
Restored ATP synthesis in dysfunctional mitochondria
Reduced mitochondrial ROS generation at source (not just downstream scavenging)
Phase 2/3 data in Barth syndrome, primary mitochondrial myopathy and dry AMD
Investigated for HFpEF, ischaemia-reperfusion injury and diabetic nephropathy
Emerging research signals in age-related mitochondrial decline and sarcopenia
These are research themes reported across the literature, not established benefits or indications.
Evidence assessment
Human trials span several mitochondrial and cardiovascular indications, with mixed efficacy results by endpoint and condition. The mechanism is well described, but success in one indication cannot be assumed in another.
What to look for
Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.
What not to assume
A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.
Protocol literature
Commonly referenced research protocols use 3–5mg subcutaneously once daily. Clinical trial dosing has ranged from 4mg to 40mg/day SC across indications (Barth syndrome, mitochondrial myopathy, HFpEF). Cycles typically run 4–12 weeks; longer daily-use protocols are cited in mitochondrial-disease research. Rotate injection sites.
Reported persistence
Plasma half-life approximately 2–4 hours; mitochondrial tissue residence and biological effect persists significantly longer through cardiolipin binding.
Calculator starting point
5 mg per reference dose
7 doses per week · 8-week cycle
3 mL default reconstitution volume
3–5 mg/day SC typical; clinical dosing ranges 4–40 mg/day depending on indication.
Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.
Calculate SS-31Laboratory handling
Reconstitution reference
Reconstitute a 30mg vial with 3mL bacteriostatic water for a 10mg/mL working concentration (0.1mL = 1mg). Swirl gently down the side of the vial — do not shake.
Storage reference
Lyophilised: 2–8°C, stable approximately 24 months; -20°C for long-term. Avoid freeze-thaw cycles. Reconstituted: 2–8°C, protect from light, use within 30 days.
Minimum documentation standard
- Record the lot identifier and review its matching analytical documentation.
- Use aseptic technique and record diluent, final volume and calculated concentration.
- Label preparation date, storage conditions and any light or freeze–thaw restrictions.
- Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Limitations & safety
Injection-site reactions (redness, itching, induration) are the most common event across clinical trials.
Phase 3 MMPOWER-3 (primary mitochondrial myopathy) missed its primary endpoint; efficacy varies by indication.
Not FDA-approved; some Phase 3 programs remain ongoing. Long-term human safety data beyond trial durations remains limited.
Research use only
This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.
Continue reading